EUS-Guided Gastroenterostomy Outperformed Surgery in Malignant Gastric Outlet Obstruction
Malignant gastric outlet obstruction demands rapid palliation. When tumor-related narrowing blocks oral intake, the immediate clinical goal is not cure but durable restoration of eating with the least physiologic burden. In a multicentre randomized superiority trial, endoscopic ultrasound-guided gastroenterostomy (EUS-GE) produced better overall outcomes than surgical gastrojejunostomy (SGJ) for patients with malignant gastric outlet obstruction.
The trial asked a direct bedside question: can an endoscopic bypass provide the same palliation as surgery while reducing recovery time, adverse events, and cost? The answer favored the less invasive approach across several clinically meaningful domains.
Composite Failure Was Less Common After the Endoscopic Approach
Investigators randomized 74 patients with malignant gastric outlet obstruction to EUS-GE or SGJ. The prespecified primary endpoint was a composite that captured persistent inability to eat, need for reintervention or supplemental nutrition, and procedure-related adverse events during 6 months of follow-up or until death. This endpoint reflects the practical consequences of palliative bypass: patients either regain function, or they remain dependent on tube feeding, repeated procedures, or prolonged hospitalization.
The composite endpoint occurred in 7.9% of patients treated with EUS-GE, compared with 38.9% in the surgical group. The risk difference was -31.0%, with a 95% confidence interval from -47.6% to -11.4%, and the difference reached statistical significance with p=0.002. In palliative upper gastrointestinal obstruction, that kind of separation is hard to dismiss. One arm allowed patients to move back toward eating; the other left a much larger share exposed to treatment failure, further nutritional support, or procedural harm.
Faster Oral Intake and Shorter Hospitalization Followed the Endoscopic Bypass
The speed with which patients returned to a solid diet favored EUS-GE. Median time to solid food was 2 days in the endoscopic group, with an interquartile range of 2 to 3 days, versus 5 days in the surgical group, with an interquartile range of 3.5 to 9 days. In malignant gastric outlet obstruction, days matter because every additional day without reliable oral intake amplifies weakness, dehydration, and nutritional decline.
Hospitalization told the same story. Median length of stay was 3 days after EUS-GE, compared with 9 days after SGJ. For patients already burdened by advanced malignancy, a six-day difference in the hospital can translate into less deconditioning, earlier return home, and more time spent outside an inpatient setting. The mechanism is straightforward: a less invasive transmural endoscopic bypass avoids the physiologic trauma of operative surgery while still creating a pathway around the obstructed outlet.
Quality of Life Improved in Domains That Matter at the Bedside
Health-related quality of life improved more after the endoscopic procedure, especially in physical and social functioning. Physical functioning favored EUS-GE with p=0.0016, and social functioning favored EUS-GE with p=0.011. Those changes fit the broader clinical pattern seen in the trial: faster resumption of intake, less time in hospital, and fewer downstream interruptions to daily life.
In patients with malignant obstruction, quality of life is not a secondary sentiment. It is the point of palliation. A procedure that restores oral intake without prolonged recovery can reduce dependence on caregivers, lessen the burden of tube feeding or repeat procedures, and allow patients to spend more of their remaining time in a home environment. The trial’s patient-reported outcomes align with that reality.
Lower Costs Reflected the Reduced Resource Burden of the Endoscopic Strategy
Treatment costs were also lower with EUS-GE. Mean cost was US$33,934 in the endoscopic group and US$51,437 in the surgical group, a difference of -US$17,503 with a 95% confidence interval from -US$27,807 to -US$7,920. Cost differences of this size usually arise from multiple stacked effects: shorter admission, fewer inpatient resources, and less need for repeat intervention or nutritional support.
That economic finding is not incidental. Malignant gastric outlet obstruction often occurs in patients with limited reserves and extensive cancer-related care needs. When a bypass strategy shortens hospitalization and reduces composite failure, the downstream financial impact follows naturally. Health systems will view this as a meaningful reduction in resource intensity, while clinicians will recognize it as a marker of a more efficient palliative pathway.
Why the Endoscopic Option May Work Better
EUS-GE combines endoscopic access with ultrasound guidance to create a bypass across the obstructed segment without the larger incision and operative stress of surgery. The biological appeal is obvious: it avoids the delay, inflammation, and recovery burden associated with an abdominal operation while still establishing a new gastrointestinal passage. In a population already weakened by malignancy, the ability to restore passage without the full physiologic cost of surgery can explain the faster return to diet and shorter length of stay.
The trial’s composite endpoint also matters because it captures the actual vulnerabilities of this patient group. A technically successful procedure is not enough if patients remain unable to eat, require reintervention, or develop adverse events that prolong care. By those standards, the endoscopic strategy delivered better palliative performance.
Trial Design Supports a Direct Clinical Comparison
This was a multicentre randomized superiority trial, which gives the comparison more weight than retrospective series or single-arm experiences that have often shaped practice in this area. Patients with malignant gastric outlet obstruction were assigned to either EUS-GE or SGJ, and the trial tracked not only procedural outcomes but also nutrition, recovery, quality of life, and costs over follow-up.
The endpoint structure was clinically disciplined. It did not rely on a single technical metric, but instead tied success to whether patients could eat, avoid further nutritional support, and escape procedure-related harm. In palliative care, that composite reflects the true burden of the disease and its treatment.
What This Means for Palliative Bypass Selection
For patients with malignant gastric outlet obstruction, EUS-GE emerged as the stronger option across the outcomes that matter most: oral intake, hospital stay, quality of life, and cost. SGJ remains an established standard, but this randomized evidence shifts the balance toward the endoscopic route when local expertise is available.
The remaining clinical question is not whether EUS-GE can work, but how broadly it can be implemented with consistent technical success across centers and operators. The trial registration number was NCT05548114, and the findings provide a clear rationale for further adoption where advanced endoscopic capability exists. Even so, the real-world durability of this approach across diverse practice settings will determine how quickly it becomes routine care.